Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203096 | 0.90 | KDM1A (0.52) | CYP3A4TSHRMAPK1KDM1AKDM1B | |
| SCHEMBL1684498 | 0.83 | CYP3A4 (0.40) | CYP3A4TSHRMAPK1KDM1AKDM1B | |
| SCHEMBL29358855 | 0.83 | CYP3A4 (0.40) | CYP3A4TSHRMAPK1KDM1AKDM1B | |
| SCHEMBL29902922 | 0.81 | ALDH1A1 (0.42) | KDM1AKDM1BALDH1A1POLBL3MBTL1 | |
| SCHEMBL966908 | 0.81 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL29502024 | 0.81 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL30711810 | 0.81 | KDM1A (0.52) | CYP3A4TSHRMAPK1KDM1AKDM1B | |
| SCHEMBL833057 | 0.81 | KDM1A (0.52) | CYP3A4TSHRMAPK1KDM1AKDM1B | |
| SCHEMBL241198 | 0.81 | ALDH1A1 (0.42) | KDM1AKDM1BALDH1A1POLBL3MBTL1 | |
| SCHEMBL457125 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025072330-A1 | KIT INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-115843191-B | Organic electroluminescent device | 北京夏禾科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
| WO-2024118887-A1 | N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-115504986-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| US-6964979-B2 | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease | WYETH (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1506201-A1 | R-ENANTIOMERS OF PYRANOINDOLE DERIVATIVES FOR TREATMENT OF HEPATITIS C | Wyeth (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| US-20040029947-A1 | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease | WYETH (US) | 2004-02-12 | — | — | US | disclosed |
| WO-2003099824-A1 | R-ENANTIOMERS OF PYRANOINDOLE DERIVATIVES AGAINST HEPATITIS C | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | CYP3A4 2266/4885TSHR 3143/4885MAPK1 171/4885 |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | CYP3A4 64/4885TSHR 384/4885MAPK1 2864/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | CYP3A4 858/4885TSHR 4635/4885MAPK1 2346/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | CYP3A4 4552/4885TSHR 4256/4885MAPK1 65/4885 |
| US-20040029947-A1 | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease | CYP3A43, CYP7A1, CYP2A13 | CYP3A4 15/4885TSHR 755/4885MAPK1 3051/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | CYP3A4 4552/4885TSHR 4256/4885MAPK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.